🇺🇸 FDA
Patent

US 10076535

Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing

granted A61KA61K31/4745A61K31/7036

Quick answer

US patent 10076535 (Use of CPG oligonucleotides co-formulated with an antibiotic to accelerate wound healing) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K31/4745, A61K31/7036, A61K31/711, A61K31/713